Fennec Pharmaceuticals Inc.

FENC Nasdaq SEC CIK 1211583
Follow Fennec Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $19.6M +57.3% vs same quarter last year
Net income $4.6M +827.3% vs same quarter last year
EPS, diluted $0.12 +700% vs same quarter last year
Operating cash flow $6.7M +347.6% vs same quarter last year
Revenue by quarter
$7.9M
$8.8M
$9.7M
$12.5M
$13.8M
$15.1M
$17.9M
$19.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$20B−$15B−$10B−$5B$0$5BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$44.6M−$9.7B
FY24$47.5M−$436M
FY23$21.3M−$16B
FY22$1.5M−$23.7M
FY21-−$17.3M
FY20$200K−$18.1M
FY19$0−$12.8M
FY18$0−$9.9M
FY17$0−$7M
FY16$0−$2.8M
FY15$0−$659K
FY14$0−$2.2M
FY13$0$1.8M
FY12$0−$5.2M
FY11$0$4.7M
MarginsShare of revenue
  • Operating margin
  • Net margin
−80000%−60000%−40000%−20000%0%20000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−14.1%−21820.3%
FY245.4%−917.2%
FY23−60.1%−75498.8%
FY22−1471.6%−1544.9%
FY21--
FY20−8942.5%−9054.5%
FY19--
FY18--
FY17--
FY16--
FY15--
FY14--
FY13--
FY12--
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$4M−$3M−$2M−$1M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13−$2.2M
FY12−$3M
FY11−$3.2M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Fennec Pharmaceuticals
  • Healthcare median
−80000%−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFennec PharmaceuticalsHealthcare median
FY25−21820.3%−30.6%
FY24−917.2%−47%
FY23−75498.8%−58%
FY22−1544.9%−80.4%
FY21-−71.8%
FY20−9054.5%−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%